Claflin Bruce L.

SEC source: 0001123292-26-001329 · form4.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spousal trust

Disclosed balance after: 8,279

F1 · kind: Reflects a contribution of common stock to an exchange fund in exchange for an interest in the exchange fund. The common stock was valued at $355.91 per share for the purpose of determining the size of the interest in the exchange fund to be issued

F2 · ownership.nature: The beneficiaries of the trust are the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the securities held by the trust.

SEC source: 0000874716-26-000100 · wk-form4_1778792415.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,354

Underlying: Common Stock · 234 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

SEC source: 0000874716-26-000100 · wk-form4_1778792415.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 525

Underlying: Common Stock · 525 shares

Expires 2036-05-11

F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001403694-26-000002 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,843

F1 · shares: Restricted stock units (RSUs) vest in full on the first anniversary of the date of the grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs).

SEC source: 0001403694-25-000012 · edgardoc.xml · nonDerivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,238

F2 · price: These shares were given as a gift for which no consideration was received by the Reporting Person.

F1 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs).

SEC source: 0001403694-25-000012 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,624

F1 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs).

SEC source: 0000874716-25-000077 · wk-form4_1746745236.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257

Underlying: Common Stock · 257 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

SEC source: 0000874716-25-000077 · wk-form4_1746745236.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600

Underlying: Common Stock · 600 shares

Expires 2035-05-06

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001403694-25-000007 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,085

F1 · shares: Restricted stock units (RSUs) vest in full on the first anniversary of the date of the grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs).

SEC source: 0001403694-25-000003 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,347

F1 · price: Reflects the weighted average sales price with transactions in a range of sales from $84.94 to $85.14. Upon request by the SEC, full information regarding the number of shares sold at each separate sales price will be provided.

F2 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs)

SEC source: 0000874716-24-000109 · wk-form4_1716238803.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161

SEC source: 0000874716-24-000098 · wk-form4_1715209240.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 863

Underlying: Common Stock · 262 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

SEC source: 0000874716-24-000098 · wk-form4_1715209240.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 609

Underlying: Common Stock · 609 shares

Expires 2034-05-05

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001403694-24-000003 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,259

F1 · shares: Restricted stock units (RSUs) vest in full on the first anniversary of the date of the grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs).

SEC source: 0000874716-23-000076 · wf-form4_168453002482219.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 601

Underlying: Common Stock · 257 shares

Expires not disclosed

F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

SEC source: 0000874716-23-000076 · wf-form4_168453002482219.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 645

Underlying: Common Stock · 645 shares

Expires 2033-05-16

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001403694-23-000002 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,821

F1 · shares: Restricted stock units (RSUs) vest in full on the first anniversary of the date of the grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs).

SEC source: 0001567619-22-010581 · doc1.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 945

Underlying: Common Stock · 945 shares

Expires 2032-05-10

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-22-010581 · doc1.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344

Underlying: Common Stock · 344 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

SEC source: 0001403694-22-000002 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,490

F1 · shares: Restricted stock units (RSUs) vest in full on the first anniversary of the date of the grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs).

SEC source: 0001567619-21-021390 · doc1.xml · nonDerivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Claflin Family Trust

Disclosed balance after: 1,560

F1 · balance_after: On November 29, 2021, the reporting person contributed 1,560 shares to the Claflin Family Trust ('Trust'), of which the reporting person's spouse is the trustee, for the benefit of the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the shares held in the Trust and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.

SEC source: 0001567619-21-021390 · doc1.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 361

F1 · balance_after: On November 29, 2021, the reporting person contributed 1,560 shares to the Claflin Family Trust ('Trust'), of which the reporting person's spouse is the trustee, for the benefit of the reporting person's spouse and children. The reporting person disclaims beneficial ownership of the shares held in the Trust and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-22-002340 · doc4.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,768

F1 · balance_after: The reporting person contributed 11,136 shares of Ciena Corporation common stock to a trust, of which the reporting person's spouse is trustee. The beneficiary of the trust is the reporting person's spouse. The reporting person disclaims beneficial ownership of the securities held by the trust. Shares reported include unvested Restricted Stock Units (RSUs) and Performance Stock Units (PSUs).

SEC source: 0001567619-21-018262 · doc1.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,921 shares

Expires 2027-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on May 3, 2018.

SEC source: 0001567619-21-018262 · doc1.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,921

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-010251 · doc1.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2031-05-11

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-21-010251 · doc1.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,552

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001403694-21-000002 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,904

F1 · shares: Restricted stock units (RSUs) vest in full on the first anniversary of the date of the grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs) and Performance Stock Units (PSUs).

SEC source: 0001567619-21-004471 · doc1.xml · derivative · entry 6

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,921

Underlying: Common Stock · 1,125 shares

Expires 2027-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Not applicable.

F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on May 3, 2018.

SEC source: 0001567619-21-004471 · doc1.xml · derivative · entry 5

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,902 shares

Expires 2026-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Not applicable.

F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the date of the 2017 annual meeting of shareholders.

SEC source: 0001567619-21-004471 · doc1.xml · nonDerivative · entry 4

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $537.15 to a high of $537.23 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-004471 · doc1.xml · nonDerivative · entry 3

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 586

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $536.13 to a high of $537.125 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-21-004471 · doc1.xml · nonDerivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,331

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-004471 · doc1.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,206

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-015709 · doc1.xml · nonDerivative · entry 3

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $384.90 to a high of $385.765 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

SEC source: 0001567619-20-015709 · doc1.xml · derivative · entry 4

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,629 shares

Expires 2025-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the date of the 2016 annual meeting of shareholders.

SEC source: 0001567619-20-015709 · doc1.xml · nonDerivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,933

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-015709 · doc1.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304

SEC source: 0001221168-20-000008 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,788

F1 · shares: Sales were effected pursuant to Rule 10b5-1 trading plan dated 06/08/2020.

F2 · price: Reflects the weighted average sales price with transactions in a range of sales from $56.005 to $56.49. Upon request by the SEC, full information regarding the number of shares sold at each separate sales price will be provided.

F3 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs) and Performance Stock Units (PSUs).

SEC source: 0001567619-20-009373 · doc1.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,279

Underlying: Common Stock · 1,279 shares

Expires 2030-05-05

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-20-009373 · doc1.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,328

Underlying: Common Stock · 370 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001403694-20-000002 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,388

F1 · shares: Restricted stock units (RSUs) vest in full on the first anniversary of the date of the grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs) and Performance Stock Units (PSUs).

SEC source: 0001403694-19-000016 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,710

F1 · shares: Sales were effected pursuant to Rule 10b5-1 trading plan dated 9/10/2019.

F2 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs) and Performance Stock Units (PSUs).

SEC source: 0001567619-19-010450 · doc1.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,404

Underlying: Common Stock · 1,404 shares

Expires 2029-05-07

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001567619-19-010450 · doc1.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,958

Underlying: Common Stock · 427 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2020 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001403694-19-000002 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,972

F1 · shares: Restricted stock units (RSUs) vest in full on the first anniversary of the date of the grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs) and Performance Stock Units (PSUs).

SEC source: 0001140361-18-035891 · doc1.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,415

SEC source: 0001140361-18-023098 · doc1.xml · derivative · entry 2

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,187

Underlying: Common Stock · 2,187 shares

Expires 2028-05-08

F3 · price: Not applicable.

F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier.

SEC source: 0001140361-18-023098 · doc1.xml · derivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,531

Underlying: Common Stock · 224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F3 · price: Not applicable.

F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.

SEC source: 0001215181-18-000014 · edgardoc.xml · nonDerivative · entry 1

Claflin Bruce L. · CIK 0001403694 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,688

F1 · shares: Restricted stock units (RSUs) vest in full on the first anniversary of the date of the grant.

F2 · balance_after: Shares reported include unvested Restricted Stock Units (RSUs) and Performance Stock Units (PSUs).